ECR Minerals plc UK Regulatory Announcement: Investor Presentation and Strategic Update
Arab Fund for Economic and Social Development Names Northern Trust Its Asset Servicing Provider
Hoffmann Green Opens Its First International Subsidiary With a Partner in Switzerland
Westchester Capital Management UK Regulatory Announcement: Form 8.3 - HomeServe plc
Wasatch Advisors UK Regulatory Announcement: Form 8.3 - Ideagen PLC
Toyoda Gosei to Invest in Interior and Exterior Parts Manufacturing Company in Central China
Senet Announces Network-Based Location Estimator
Westchester Capital Management UK Regulatory Announcement: Form 8.3 - Avast plc
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange
-
DIGITIMES: Why are Smart Cities the Future Momentum
TAIPEI, July 6, 2022 /PRNewswire/ -- DIGITIMES Research report shows that Taiwan's ICT industry development has shifted from focusing on hardware to hardware/software integration models. The industry is combining big data analysis and AI applications in public IoT to facilitate the development of smart city management. Tools such as IoT, AI, cloud computing, and communications technologies are efficiently integrated with urban infrastructure to ultimately produce economic benefits and improve quality of life. It is estimated that the business opportunities of smart cities will reach $2.6 trillion in 2025, mainly in the Asia Pacific region. This includes sectors such as smart poles, building, parking, monitor, government, transportation, fire protection, water conservancy and WITMED. Smart cities, with a massive business potential, will become the future momentum! DIGITIMES will have Dr. Ayesha Khanna, Co-Founder and CEO of Addo, to share her observation of new smart city applications as well as how technologies can improve people's life and government efficiency on July 21 smart city webinar. In the pre-event interview that asked about Taiwan's role in the smart city market, Dr. Khanna pointed out that Taiwan's expertise in semiconductor and hardware is important to smart cities' development as more data is being used to improve AI systems, resulting in rising demand for stronger infrastructure and hardware with next-generation AI semiconductors. Dr. Khanna believes that whether it is AI, robots, 3D printing, Internet of things or 5G, smart city's development should not start purely with technologies but the idea of assisting people to solve their problems or become the aspirational goal for citizens. When people want to have better energy and waste management in their city, designers can create an AI solution for monitoring energy usage that can turn streetlights on and off with a built-in smart lighting system. They can also build a centralized trash collection mechanism with sensors and have robots powered by AI to collect waste all around the neighborhoods to reduce traffic and road congestions. It is also important to collect and integrate publicly available data and data from the ecosystem's private firms to form a system. By combining data of taxi companies and traffic light operation, it reduces people's waiting time for taxies, while traffic congestion can also be significantly lowered with the system's assistance in rerouting or changing the traffic lights. Nowadays, because of the pandemic, the number of hospital visits via online meeting software or telemedicine services increased dramatically as people find it more convenient and efficient. The technologies used by medical care system are also making improvements with some designers beginning to adopt biometric sensors onto the terminals for the machines to collect more patients' data, giving doctors more information to make intelligent diagnosis, such as handheld ultrasound products that can be connected via smartphones for patients to check on themselves via AI or by medical staff nearby and then send results to their doctors. Technologies for remote medical care are a key area that many IT companies have devoted their R&D effort to. Ambulances built with remote medical care system can connect doctors with ambulances care assistants for them to do checkups while transporting patents to the hospital. The doctors can also make an examination over patients' injuries via a head-mounted display (HMD) to save time. However, all these innovations still rely on 5G to form connections. The technology allows devices to communicate with each other with its fast transmission speed and has brought a revolution to the manufacturing industry and factories. In Singapore, a lot of investments are being made for deploying 5G infrastructure throughout the city. This is also the case for many countries including the US. As smart systems are adopting more sensors to enhance their data collection ability, 5G's commercialization has become the key to unlock the potential of IoT. With telecom carriers worldwide keenly expanding their 5G infrastructure, Dr. Khanna is optimistic about the birth of more new smart systems and the rapid development of smart cities worldwide soon. In the end, the future of smart city will not be operated by one large central AI, but multiple small ones. Issues within smart cities' key sectors such as healthcare, energy and education will continue to be handled by government departments or public sector companies with them using AIs to optimize and create innovations for their services, Dr. Khanna said. Join DIGITIMES Asia smart city webinar in discovering the digital transformation of smart cities, find out how to build a smart city, and what are the applications and connected solutions that drive city extensive improvements, creating better quality of life for residents and business opportunities for enterprises. For more webinar information, please visit https://reurl.cc/j1KRgZ
-
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
– Mosunetuzumab could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin’s lymphoma – – Application is based on results from the pivotal Phase I/II study showing mosunetuzumab induced high and durable complete response rates in people with follicular lymphoma who received two or more prior therapies – – Mosunetuzumab is a fixed-duration treatment option with the potential to be administered in an outpatient setting – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Biologics License Application (BLA) and granted Priority Review for mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, for the treatment of adults with relapsed or refractory (R/R) follicular lymphoma (FL) who have received at least two prior systemic therapies. FL is the most common indolent (slow growing) form of non-Hodgkin’s lymphoma (NHL), a type of blood cancer, which often returns after initial therapy. The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022. “New therapeutic options are needed for follicular lymphoma, which often relapses after initial therapy and becomes increasingly difficult to treat each time it returns. Clinical trial results have demonstrated durable responses with mosunetuzumab in advanced follicular lymphoma, representing a step toward shifting the treatment paradigm,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Since mosunetuzumab does not require the collection or genetic modification of patient cells, it could become an effective, fixed-duration outpatient option without the barriers of travelling to a major academic center.” The BLA is based on positive results from the pivotal Phase I/II GO29781 study of mosunetuzumab, which showed high complete response (CR) rates, with the majority of responders (57% [95% CI: 49-70]) maintaining responses for at least 18 months, and manageable tolerability in people with heavily pretreated FL. After a median follow-up of 18.3 months, the CR rate was 60% (n=54/90) and the objective response rate was 80% (n=72/90). The median duration of response among those who responded was 22.8 months (95% CI: 9.7-not estimable). The most common adverse event (AE) was cytokine release syndrome (39%; n=86/218), which was generally low grade (grade 1: 25.6%; grade 2: 14%; grade 3: 2.3%; grade 4: 0.5%), and all events resolved. Other common AEs (>20%) included fatigue, headache, neutropenia, fever and hypophosphatemia. Treatment was administered without mandatory hospitalization. Results were presented for the first time in December 2021 at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition. Priority Review designation is granted to medicines that the FDA considers to have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease. The FDA granted Breakthrough Therapy Designation (BTD) to mosunetuzumab for the treatment of adults with R/R FL who have received at least two prior systemic therapies in June 2020 and Orphan Drug Designation in December 2018. BTD is designed to accelerate the development and review of medicines intended to treat serious or life-threatening conditions with preliminary evidence that indicates they may demonstrate substantial improvement over existing therapies. The European Commission granted conditional marketing authorization for mosunetuzumab for the treatment of people with R/R FL who have received at least two prior systemic therapies in June 2022. A robust development program for mosunetuzumab is ongoing including two Phase III studies: CELESTIMO investigating mosunetuzumab plus lenalidomide in second-line plus (2L+) FL, and SUNMO, investigating mosunetuzumab plus Polivy® (polatuzumab vedotin) in 2L+ diffuse large B-cell lymphoma (DLBCL). About the GO29781 Study The GO29781 study [NCT02500407] is a Phase I/II, multicenter, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of mosunetuzumab in people with relapsed or refractory B-cell non-Hodgkin’s lymphoma. Outcome measures include complete response rate (best response) by independent review facility (primary endpoint), objective response rate, duration of response, progression-free survival, safety and tolerability (secondary endpoints). About Follicular Lymphoma Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkin’s lymphoma, accounting for about one in five cases. It typically responds well to treatment but is often characterized by periods of remission and relapse. The disease typically becomes harder to treat each time a patient relapses, and early progression can be associated with poor long-term prognosis. In the United States, it is estimated that approximately 13,000 new cases of FL will be diagnosed in 2022. About Mosunetuzumab Mosunetuzumab is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for mosunetuzumab is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma, diffuse large B-cell lymphoma and other blood cancers. About Polivy® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Seagen ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat diffuse large B-cell lymphoma in adults who have progressed after at least two prior therapies. The accelerated approval of Polivy is based on a type of response rate. There are ongoing studies to confirm the clinical benefit of Polivy. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. A patient’s doctor may stop or adjust a patient’s treatment if any serious side effects occur. Patients must contact their healthcare team if there are any signs of these side effects. Nerve problems in arms and legs: This may happen as early as after the first dose and may worsen with every dose. If a patient already has nerve pain, Polivy may make it worse. The patient’s doctor will monitor for signs and symptoms, such as changes in sense of touch, numbness or tingling in hands or feet, nerve pain, burning sensation, any muscle weakness, or changes to walking patterns Infusion-related reactions: A patient may experience fever, chills, rash, breathing problems, low blood pressure, or hives within 24 hours of the infusion Infections: Patients should contact their healthcare team if they experience a fever of 100.4°F or higher, chills, cough, or pain during urination. Also, a patient’s doctor may give medication before giving Polivy, which may prevent some infections, and monitor blood counts throughout treatment with Polivy. Treatment with Polivy can cause severe low blood cell counts Rare and serious brain infections: A patient’s doctor will monitor the patient closely for signs and symptoms of these types of infections. Patients should contact their doctor if they experience confusion, dizziness or loss of balance, trouble talking or walking, or vision changes Tumor lysis syndrome: Caused by the fast breakdown of cancer cells. Signs include nausea, vomiting, diarrhea, and lack of energy Potential harm to liver: Some signs include tiredness, weight loss, pain in the abdomen, dark urine, and yellowing of the skin or the white part of the eyes. Patients may be at higher risk if they already have liver problems or are taking other medication Side effects seen most often The most common side effects during treatment were: Low blood cell counts (platelets, red blood cells, white blood cells) Nerve problems in arms and legs Tiredness or lack of energy Diarrhea Nausea Fever Decreased appetite Infections Polivy may not be for everyone. A patient should talk to their doctor if they are: Pregnant or may be pregnant: Data have shown that Polivy may harm an unborn baby Planning to become pregnant: Women should avoid getting pregnant while taking Polivy. Women should use effective contraception during treatment and for at least 3 months after their last Polivy treatment. Men taking Polivy should use effective contraception during treatment and for at least 5 months after their last Polivy treatment Breastfeeding: Women should not breastfeed while taking Polivy and for at least 2 months after the last dose These may not be all the side effects. Patients should talk to their healthcare provider for more information about the benefits and risks of Polivy treatment. Report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch. Report side effects to Genentech at (888) 835-2555. Please visit http://www.Polivy.com for the full Prescribing Information for additional Important Safety Information. About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology. About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com. Contacts Media Contact: Priscilla White (650) 467-6800 Advocacy Contact: Cem Mangir (202) 251-4037 Investor Contacts: Loren Kalm (650) 225-3217 Bruno Eschli 011 41 61 687 5284
-
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
SAN DIEGO and HONG KONG and SYDNEY, July 6, 2022 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") and HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) announces today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a multi-stage, double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers, and a dose-escalation and parallel design, multiple-dose study in adult patients with moderate to severe atopic dermatitis. The study will be used to evaluate the safety, tolerability and efficacy of IMG-007 in patients with atopic dermatitis. Additional details will be found at clinicaltrials.gov, using identifier NCT05353972. "Dosing the first participant is an important milestone for the IMG-007 program," said Dr Jonathan Wang, Chairman and Chief Executive Officer of Inmagene. "We hope the data will help us demonstrate that IMG-007 is one of the strongest OX40 antagonist drug candidates worldwide." Dr Jean-Louis Saillot, Chief Development Officer of Inmagene, said, "IMG-007 blocks the OX40 activity and has demonstrated high potency in preclinical studies, indicating a best-in-class potential. We welcome the start of the IMG-007 clinical program with the hope of developing an innovative, safe and effective treatment option for patients with atopic dermatitis and other immunological diseases." Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said: "This is an exciting step towards taking our novel drug candidates into immunological diseases, where Inmagene has significant expertise, as we work to maximize the impact of our drug discovery engine." About IMG-007 IMG-007 is a novel antagonistic monoclonal antibody targeting the OX40 receptor. It was originally discovered by HUTCHMED, with Inmagene assuming development responsibility at the candidate stage. Inmagene has an exclusive option to in-license IMG-007's global rights. About OX-40 and Atopic Dermatitis OX40 is a costimulatory receptor member of the tumor necrosis factor receptor (TNFR) superfamily expressed predominantly on activated T cells. The ligation of OX40 by its ligand OX40L leads to enhanced T cell survival, proliferation, and effector functions. Preclinical research results show that IMG-007 can bind to human OX40 receptor with high affinity, thereby inhibit the binding of OX40 to OX40L, reducing OX40L-dependent downstream signaling and cytokine release by OX40+ T cells. By selectively shutting down OX40+ T cell function, IMG-007 may provide a treatment option for pathological OX40+ T cell-mediated immune diseases, such as atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin condition that is estimated to affect 8-19% of children and 2-5% of adults in US, Europe, and East Asia.[1],[2],[3] About Inmagene Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building a robust pipeline of nearly twenty drug development programs. Inmagene's most advanced drug candidate is IMG-020 (izokibep), which has successfully met the endpoints in global phase II studies for both psoriasis and psoriatic arthritis ("PsA"). It has received the IND approval from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) for phase III studies in plaque psoriasis. Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis. In addition, IMG-004 and IMG-007, both of which with global rights, are in global phase I studies. Believing in "Borderless Innovation", the Inmagene team strives to integrate efficient resources worldwide to develop novel therapeutics for global patients. Based on its proprietary QuadraTek™ drug discovery platform, Inmagene is operating 12 "Smart Innovation" programs to create and develop drug candidates with global rights. Inmagene also in-licenses drug candidates and, together with its partners, carries out global development activities, including global multi-center clinical trials. Inmagene has formed strategic partnerships with multiple partners, such as HUTCHMED and Affibody AB, to develop highly innovative drug candidates. For more information, please visit: www.inmagenebio.com About HUTCHMED HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has more than 4,900 personnel across all its companies, at the center of which is a team of over 1,800 in oncology/immunology. Since inception it has advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch-med.com or follow us on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect Inmagene's and/or HUTCHMED's current expectations regarding future events, including expectations regarding the therapeutic potential of IMG-007 for the treatment of patients with atopic dermatitis and other immunological diseases, the further clinical development of IMG-007, expectations as to whether clinical studies of IMG-007 would meet their primary or secondary endpoints, and expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding enrollment rates and the timing and availability of subjects meeting a study's inclusion and exclusion criteria; changes to clinical protocols or regulatory requirements; unexpected adverse events or safety issues; the ability of IMG-007 to meet the primary or secondary endpoint of a study, to obtain regulatory approval in different jurisdictions and to gain commercial acceptance after obtaining regulatory approval; the potential market of IMG-007 for a targeted indication; the sufficiency of funding; and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of various risks applicable to HUTCHMED, see HUTCHMED's filings with the U.S. Securities and Exchange Commission, on AIM and with The Stock Exchange of Hong Kong Limited. Neither Inmagene nor HUTCHMED undertakes to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise. [1] Silverberg JI, Barbarot S, Gadkari A, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. Ann Allergy Asthma Immunol. 2021;126(4):417-428.e2. doi:10.1016/j.anai.2020.12.020 [2] Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: Results from an international survey. Allergy. 2018;73(6):1284-1293. doi:10.1111/all.13401 [3] Ständer S. Atopic Dermatitis. N Engl J Med. 2021;384(12):1136-1143. doi:10.1056/NEJMra2023911
-
K-SWISS Athlete, Cameron Norrie, Beats David Goffin to Advance to the Semi-Finals at Wimbledon
LOS ANGELES, July 6, 2022 /PRNewswire/ -- Iconic American heritage Tennis brand, K-SWISS, is thrilled to announce their sponsored athlete, Cameron Norrie, will advance to the Semi Final round at Wimbledon after beating David Goffin in an exciting 5 set match. The #1 ranked British player, who is currently ranked #12 ATP seeks to continue his best run ever at a Grand Slam title. Norrie has been a K-SWISS athlete since 2020. "Our partnership with Cam began three years ago. We liked this playing style and approach to owning everything he does on court. Last year we could see his improvement and confidence grow with every match, starting 2021 ranked in the seventies and finishing the year at number ten. As we continue to invest in our tennis business globally, re-signing Cam to be our global ambassador was a top priority, we were very excited and proud for Cam to be part of our K-Swiss Team through 2024," says Dave Grange, International Brand President of K-Swiss. During the match, Norrie's footwear of choice continues to be the K-SWISS Ultrashot 3. The new shoe is built for the competitive, aggressive, and powerful tennis player who demands the highest level of performance. The Ultrashot 3 offers maximum energy return with Surge 7.0 midsole technology, 360 Plantar Chassis Support for unlimited lateral movement, and Dragguard 7.0 incorporated into a new durable outsole with superior grip and traction. In addition to the footwear, Norrie is also wearing the newly redesigned K-SWISS apparel, the Heritage S/S shirt and the Supercharge shorts, which are innovatively designed for fit and function. The lightweight materials incorporated with stealth angles and asymmetrical side create an aerodynamic progressive look that redefines the classic tennis outfit. Today, Norrie looked and played like a champion. The K-SWISS styles similar to what Norrie wore today at Wimbledon are available on K-Swiss.com. ABOUT K-SWISS From the beginning, K-Swiss has been driven by an entrepreneurial spirit when two Swiss brothers moved to California to create a footwear brand focused on tennis. As avid skiers, the brothers took inspiration from leather ski boots to create tennis shoes that supported the aggressive side-to-side movement. Introduced In 1966, the K-Swiss Classic was the world's first all-leather tennis shoe. It quickly gained worldwide acclaim and became a style statement both on and off the court, worn casually in country clubs and just as fashionably on city streets. Now, 57 years later, K-Swiss is building from its heritage as an American tennis brand and writing new chapters in its storied history. Paying homage to the hard work of our founders and the competitive nature of the game that inspired it all, K-Swiss is dedicated to outfitting and inspiring the next generation of tennis players. Media Contacts:K-SWISSOlivia@kruppgroup.com Cameron Norrie (Photo by Justin Setterfield/Getty Images)
-
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Missfresh Limited with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Missfresh Limited (“Missfresh” or “the Company”) (NASDAQ: MF) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Missfresh announced on July 1, 2022, that an internal review revealed that certain revenues in fiscal 2021 “may have been inaccurately recorded.” According to the Company, the review uncovered “questionable transactions” recorded by the Next-Day Delivery Business Unit, including “undisclosed relationships between suppliers and customers, different customers or suppliers sharing the same contact information, and/or lack of supporting logistics information.” If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Edgio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgio, Inc. (“Edgio” or “the Company”) (NASDAQ: EGIO) f/k/a Limelight Networks, Inc. (NASDAQ:LLNW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com. The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
Deep Longevity Announces Important Operational Update
HONG KONG, July 6, 2022 /PRNewswire/ -- Endurance RP Limited's ("Endurance Longevity" or the "Company" and together with its subsidiaries, the "Group"; stock code: 0575.HK) wholly owned subsidiary Deep Longevity, Inc, a Hong Kong-based AI innovator and a leading provider of deep biomarkers of aging and longevity is pleased to announce several important updates which contribute to its growing journey. Hiring of New Chief Executive Officer Deep Longevity has hired a new Chief Executive Officer, Deepankar (Deep) Nayak, to bring experienced professional talent to redefine the strategy of the company, and take the organisation forward. Deep has over 17 years of experience in technology consulting having worked with large pharmaceutical customers in the United States ("US"), United Kingdom ("UK"), Europe, Japan and the Middle East. Building and Commercialisation of Aging Clocks Deep Longevity is committed to building and commercialising various aging clocks using artificial intelligence ("AI") led deep learning models. The company is applying special focus to the MindAge© offering as it seek to tap into the robust demand seen in the virtual mental health care market. The total addressable market is approximately US$89 billion (or approximately HK$694.2 billion) in the US only. MindAge© Deep Longevity is considering the creation of an enterprise grade MindAge© offering (web and app based) directed at large and mid-sized employers in the US, UK and Europe, which will be the platform of choice for employees to manage their virtual mental well-being in a safe, secure, private and personalized environment within the workplace. This will be the company's main focus for 2022 and 2023. Collaboration with Dr. Nancy Etcoff Deep Longevity announced its collaboration with Dr. Nancy Etcoff of Harvard Medical School on 21 June 2022 to create a virtual mental health offering through the deep learning based biomarkers of aging and longevity. In co-authorship with Dr. Etcoff, Deep Longevity has published an article in Aging-US describing a machine learning approach to human psychology: "Optimizing future well-being with artificial intelligence: Self-organizing maps (SOMs) for the identification of islands of emotional stability." Development of FuturSelf FuturSelf, a free self-help application has been developed in collaboration with a leading European insurtech innovation hub to demonstrate the potential of the system. Data obtained on FuturSelf will be used to further develop Deep Longevity's digital approach via a minimal viable product (MVP) on mental health with the aim of offering the application via a business-to-business (B2B) software as a service (SaaS)© model to insurance companies, large corporates and other employers to allow their employees to track and nurture their own mental health and wellbeing. To address how mental health can be managed to help employees better cope with job demands and maximize their productivity, Deep Longevity is focused on providing highly scalable and commercial solutions that can be applied cost effectively across all industries. Using Deep Longevity's digital approach to managing mental health, an invaluable feedback loop is created that can help employees thrive by increasing their motivation and productivity or allowing them to seek important and timely emotional support when required. On a per-employee basis, the cost to employers to provide this essential human resource function can be minimal. Ongoing discussions with large insurance companies and other multinational corporations suggest that the commercial opportunity for Deep Longevity (through FuturSelf and other applications) is immense and geographically scalable across all markets world-wide. Jamie Gibson, Chief Executive Officer of the Company said, "As one of the forerunners in the longevity AI market, we are thrilled to achieve this remarkable milestone together with the world's top-notch scientists. We are confident about the future of integrating deep learning AI technologies in human psychology and the development of digital solution to improve people's mental health and overall well-being." Alex Zhavoronkov, Chief Longevity Officer of Deep Longevity commented, "I've dedicated a large part of my life towards furthering the science of Longevity and am delighted to announce that DL has found a person who not only shares that passion but also brings the experience of building and commercializing products that will help us take our innovation to global markets. DL's aging clocks will underpin the research and development that the Longevity industry is going to witness and I'm confident Deep will take our aging clocks to different industries as we discover new applications of this technology." -Ends- About Deep Longevity Deep Longevity is a wholly owned subsidiary of Endurance Longevity (SEHK:0575.HK), a publicly-traded company. Deep Longevity develops explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine, which enables physicians to make better decisions about interventions that may slow down or reverse the aging processes. Deep Longevity developed the Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity began its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence: ETP Ventures; the Human Longevity and Performance Impact Venture Fund; BOLD Capital Partners; Longevity Vision Fund; LongeVC; Michael Antonov, the co-founder of Oculus; and other expert AI and biotechnology investors. Deep Longevity established a research partnership with Human Longevity, Inc., one of the most prominent longevity organizations to provide a range of aging clocks to a network of advanced physicians and researchers. https://www.deeplongevity.com/ About Endurance Longevity (Stock code: 0575.HK) Endurance Longevity is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering. www.endurancerp.com This press release is distributed by LBS Communications Consulting Limited.
-
How Javer Became One of the Best Companies to Work in Mexico
MONTREAL--(BUSINESS WIRE)--Reaching a genuine sustainability strategy that engages all stakeholders with the utmost care and respect is crucial for companies seeking to build solid long-term results. Today, employees, consumers, and investors are constantly looking for companies that embrace a holistic business approach. Javer has become a benchmark of sustainability in Mexico, especially in human resources management, which has allowed it to be recognized as one of the best companies to work for in Mexico. Great Place To Work (GPTW) is an international certification awarded to companies that create an exceptional workplace environment. GPTW uses the Trust Index, a KPI (key performance indicator) for measuring the commitment of the people who are part of the company; the higher it is, the greater the trust. This certification has 5 dimensions: credibility, respect, fairness, pride, and camaraderie. GPTW survey has allowed Javer to measure, track, and strengthen different aspects that contribute to the quality of working life. The company has historically stood out in two categories: pride and camaraderie, thanks to its friendly working environment, as multiple activities are carried out to forge strong bonds and establish good communication among leaders and employees, which is reflected in its employees expressing a sense of pride being part of this company. Javer's high ranking on the list is the result of the implementation of several programs, including: Approach on talent retention: The company provides different benefits and perks to employees to encourage their professional growth. Equality and diversity: Javer is attached to the principles of inclusion, empathy, and, tolerance, highlighting the fact that its team has a significant number of women holding leadership positions, as well as the pursuit of equal opportunities for all. Occupational health and safety: Javer is committed to ensuring an excellent quality of life for its employees. This encompasses topics such as mental health, nutrition, information sessions on COVID-19. Over the past years, Javer has steadily improved in the GPTW's national ranking within the 500 to 5,000 employee Top 100 Companies category. In 2022, it ranked 35th, with much further progress. There is no doubt that Javer's success in the management of its human resources will allow it to continue consolidating its position as one of the best Mexican companies in the construction industry. Read the full release at: Emerging Exchange Contacts Marijose Vasquez info@emergingexchange.com+1 646 419 4004
-
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Radius Health, Inc. with Losses to Contact the Firm
LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Radius Health, Inc. (“Radius” or “the Company”) (NASDAQ: RDUS) for potential breaches of fiduciary duty on the part of its directors and management. If you are a shareholder who has held shares of Radius purchased prior to June 23, 2022, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at bschall@schallfirm.com. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. Contacts The Schall Law Firm Brian Schall, Esq. 310-301-3335 info@schallfirm.comwww.schallfirm.com
-
harrison.ai and Sonic Healthcare join forces to launch 'franklin.ai', bringing Artificial Intelligence (AI) to pathology
franklin.ai aims to apply the latest methodologies in artificial intelligence (AI) to put groundbreaking AI tools into the hands of pathologists. SYDNEY, July 6, 2022 /PRNewswire/ -- harrison.ai, the clinically led healthcare AI platform and Sonic Healthcare (ASX:SHL), the global medical diagnostics leader, have this week officially launched 'franklin.ai', a joint venture to advance patient care by integrating digital pathology tools into daily clinical practice. The global partners have appointed Stephen Ruffels as Chief Executive Officer of franklin.ai, bringing 20 years of technology leadership and medical device experience to the newly formed venture. Stephen, formerly harrison.ai's Chief Operating Officer, will oversee a team of more than 70 specialist engineers, data scientists and clinical experts by the end of 2023 to rapidly develop and commercialise new artificial intelligence (AI) methodologies for pathology. franklin.ai will provide pathologists with a digital assistant, using state-of-the-art AI technology in the form of tools that enhance diagnostic accuracy and efficiency. The venture combines harrison.ai's depth of expertise and comprehensive AI methodologies with Sonic Healthcare's global clinical experience and expertise to unlock the potential of digital pathology. The new venture is supported by key hires, including General Manager Peter Dassos (formerly Director of Product at ResMed), and Head of Talent Celeste Kocabay (formerly Atlassian and Investible). Stephen Ruffels, CEO of franklin.ai, said: "The global healthcare system has changed, and today we face many new challenges that require groundbreaking technological and digital advancements. We have spent months building the right team to work hand-in-hand with pathologists to develop AI-powered tools that will augment their pivotal role at the heart of the healthcare system. We are excited to see the partnership between harrison.ai and Sonic Healthcare grow stronger by the day." Dr Aengus Tran, Co-Founder and CEO of harrison.ai, said: "The launch of franklin.ai marks a milestone in our partnership with Sonic Healthcare. Combining the harrison.ai process and technology platform with Sonic Healthcare's expertise is what we believe to be the fastest way to achieve our common goal of improving the capacity and quality of pathology services globally." "We are also thrilled to announce that our former COO, Stephen Ruffels, has been appointed as CEO of franklin.ai. Stephen was one of the first to join us and has contributed enormously to the success of harrison.ai in the last two years. I am confident that Stephen will uphold the values of both harrison.ai and Sonic Healthcare with his leadership and expertise in medical devices and will drive our mission in the pathology sector." Dr Colin Goldschmidt, CEO of Sonic Healthcare, adds, "I am delighted with our new partnership, one which will strengthen our digital pathology endeavours on a global scale. Laboratory medicine informs almost every aspect of modern medicine, especially the diagnosis of cancer. With franklin.ai, we are taking a big step forward in the field of digital pathology, and we look forward to playing a leadership role in this important new area of modern medicine." - END - About franklin.ai franklin.ai is a joint venture between global medical diagnostic leader Sonic Healthcare and healthcare AI platform harrison.ai with a mission to put groundbreaking artificial intelligence (AI) in the hands of pathologists globally and benefit millions of patients. About harrison.ai harrison.ai is a clinician-led technology platform combining human intelligence with artificial intelligence (AI), building a range of ventures to change the face of healthcare and benefit millions of patients every day. With a vision to redefine what's possible in healthcare through AI technology, harrison.ai works with ventures to develop, commercialise and deploy AI tools that support clinical diagnosis. These include working with Virtus Health Limited to develop AI in IVF and the world's most comprehensive AI clinical decision-support solutions for diagnostic imaging in its venture with I-MED Radiology Network annalise.ai. Most recently, partnering with Sonic Healthcare to put AI tools in the hands of pathologists with franklin.ai. Each venture is based on the harrison.ai platform and fuses harrison.ai's partner company's deep clinical expertise and frameworks with the harrison.ai technology. About Sonic Healthcare Sonic Healthcare is one of the world's leading providers of medical diagnostics, with a reputation for excellence in laboratory medicine/pathology, radiology and primary care medical services, across operations in Australasia, Europe and North America.
-
EML Collaborates With Correos On A €210 Million Spanish Government Economic Stimulus For 500,000 Youths In Culture & Arts
MADRID--(BUSINESS WIRE)--EML Payments Limited (ASX: EML) and its partner and key European client, Correos, Spain's national post office network, will support the issuing of a government contract known as the Bono Cultural Joven 2022 (Youth Cultural Bonus) tender. Approximately 500,000 virtual prepaid cards will be issued and loaded with a government stimulus totalling €210 million in support of the culture sector, which was badly hit during COVID. Direct aid of €400 on an instant virtual card, which can be upgraded to a physical card, will be given to each eligible young person in Spain who turns 18 in 2022. The funds can be spent on various cultural products and activities, including the performing arts, live music, films, libraries, museums, festivals, sheet music, records, books, audiobooks and magazines. The stimulus programme, part of Spain's General State Budgets, will see €210 million pumped into the country's economy over the next 12 months. The government will promote the new aid programme to revitalise and stimulate the cultural sector in Spain, guaranteeing the sustainability of the cultural and creative industries after the negative impact of the pandemic. It also promotes universal and diversified accessibility to culture, promoting loyalty amongst young people to generate the habit of consuming cultural products. Approximately 500,000 eligible 18-year-olds will receive their €400 stimulus allocation on a virtual card via a single payment. ''We're very happy to be able to collaborate with the Ministry to promote culture amongst young people. This project, which is part of the Correos Prepago business line, positions Correos as a benchmark for the delivery of social aid and financial inclusion within the company's strategic framework of diversification,'' said Manuel Zapatero Sierra, Director of Products & Services at Correos. ''Our business relationship with Correos goes back a long way, and we've achieved many milestones together. We're delighted to continue to build on this partnership with such a significant and important initiative in helping support the arts sector across Spain,'' said Emilio Gutierrez, Head of Spain at EML. EML’s economic and emergency disbursement track record extends to governments and international aid organisations in Europe, Australia, and the U.S. Correos is one of the leading Spanish companies by size, presence and human capital, with 84 million post office visitors annually across Spain, providing rapid access to Spain's youth population. About Correos: Correos was born more than 300 years ago and, after continuous adaptation to the market, today it is the leading operator in the sector in Spain. Currently, the company's strategy is focused on internationalisation, sustainability and digital transformation. With nearly 51,000 professionals, the company provides services to citizens through its network of 2,370 offices, distributing nearly 7.5 million shipments daily. The Correos Group has 3 subsidiaries: Correos Express, dedicated to urgent parcels, Nexia, specialised in multi-channel solutions for communications in massive companies and Correos Telecom, in charge of the management and commercialisation of telecommunications infrastructures. Belonging to the SEPI Group, it is part of a business holding that encompasses a total of 15 public enterprises. About EML Payments EML provides an innovative payment solutions platform, helping businesses all over the world create awesome customer experiences. Wherever money is in motion, our agile technology can power the payment process, so money can be moved quickly, conveniently and securely. We offer market-leading programme management and highly skilled payments expertise to create customisable feature-rich solutions for businesses, brands and their customers. Come and explore the many opportunities our platform has to offer by visiting us at: EMLPayments.com Read more EML stories by visiting our Newsroom: https://www.emlpayments.com/newsroom/ Sources: Correos Group’s key figures https://www.correos.com/en/grupo-correos/#cifras-claveBono Cultural Joven website https://www.culturaydeporte.gob.es/destacados/bono-cultural-joven.htmlSpain’s Ministry of Culture & Sports’ statement https://www.culturaydeporte.gob.es/actualidad/2022/06/220624-bono-cultural-correos.htmlCorreos' boilerplate https://cswetwebcorsta01.blob.core.windows.net/uploads/2022/06/2022_06_21-NP-Correos-Market-colabora-con-Palomo-Spain-dentro-de-su-apuesta-por-el-talento-espanol.pdf Contacts Sarah Bowles, Group Chief Digital OfficerEML Payments Limited (ASX: EML)sbowles@emlpayments.com+61 439 730 968 Marie O’Riordan, Global Director of Public RelationsEML Payments Limited (ASX: EML)marie.oriordan@emlpayments.com / pr@emlpayments.com+44 207 183 5856
-
VISEO Completes the Acquisition of Warp to Expand Digital Services Offering in Japan
TOKYO & SINGAPORE--(BUSINESS WIRE)--VISEO, a global technology company specializing in digital transformation services and Warp Japan (Warp), a boutique digital agency specializes in helping Japanese and International brands with their digital strategy, have announced a tie-up to grow its reach in Japan. The acquisition enables VISEO to accelerate its reach by leveraging Warp’s proven capabilities in the digital services space. It provides digital marketing, content creation, interactive installation, design and development for web, mobile and e-commerce websites. On the other hand, VISEO delivers end-to-end guidance for IT services, ranging from application development, system integration to digital solutions, and capture opportunities across industries. The synergies created will further strengthen VISEO’s capabilities in Japan and in the entire Asian Pacific Japan region. Nao Sato, CEO of Warp, says, “We’re excited by VISEO’s strategy and plans to grow their digital transformation and optimization capabilities across the Asia Pacific and Japan. Joining VISEO presents a strategic opportunity for us to drive the acceleration of digital solutions across a variety of industries.” With VISEO’s global presence and a 20-year strong foothold in the IT consulting firm, VISEO supports companies that need to reinvent themselves by taking advantage of technological opportunities making them more efficient. “We are delighted to have Warp Japan coming onboard our VISEO family. This acquisition helps accelerate our expansion in Japan. It also provides a greater value for our clients in the Asia Pacific Japan region through building an innovation ecosystem for technology players, to augment our service portfolio and give our clients access to agility plus innovation across the region.” says Olivier Dhonte, Chairman of VISEO Group. For more information, please visit https://www.warpjapan.com/ and https://www.viseo.com/ ### About Warp Japan Warp Japan is a boutique digital agency based in Tokyo, specializes in Japanese and International brands with their digital strategy. With a team of international and skillful in-house experts who are passionate about new technologies and eager to create the perfect digital content for its clients. Warp Japan has helped endless international brands engage with their target audience by humanizing the way they present themselves and how they speak to their consumers. About VISEO VISEO is a global IT consulting firm specializing in assisting its clients with their IT and digital transformation. VISEO uses technology as a powerful lever of transformation and innovation to help its clients take advantage of digital opportunities, address new usages and compete with new players who change the rules of the game. With more than 2,500 employees across five continents, VISEO combines agility and complementarity of its areas of expertise – design of new products and services, digitization of business processes, data valuation, digital assets development - making digital a real lever of competitiveness and performance. Contacts For media enquiries and further information, please contact: Helene Sigrand VP Marketing & Communication, VISEO helene.sigrand@viseo.com Nao Sato CEO, Warp Japan sato@warpjapan.com
-
Adyen provides omnichannel payments services to UNIQLO
Adyen financial technology platform supports Fast Retailing move to strengthen omnichannel payments. AMSTERDAM, July 6, 2022 /PRNewswire/ -- Adyen (AMS: ADYEN), the financial technology platform of choice for leading companies, has been chosen by Fast Retailing, operator of UNIQLO, to power payments for the brand's in-store and online checkout in multiple markets. Photo courtesy of Fast Retailing The integration with Adyen removes the need for multiple supplier contracts, allowing UNIQLO to easily consolidate and reconcile payments information across multiple channels. This single platform gives UNIQLO the flexibility to do faster rollouts of omnichannel services. "We're pleased to enable Fast Retailing in implementing a truly customer-centric structure that uses innovation to provide a great UNIQLO experience," said Pieter van der Does, co-founder and CEO of Adyen. "It's exciting to shop in a UNIQLO store in Amsterdam and know you'll have the same checkout experience in other markets. We're excited to enable Fast Retailing in using innovation to offer a truly customer-centric omnichannel experience that underscores the exceptional service shoppers have come to expect from the UNIQLO brand." About Adyen Adyen (AMS: ADYEN) is the financial technology platform of choice for leading companies. By providing end-to-end payments capabilities, data-driven insights, and financial products in a single global solution, Adyen helps businesses achieve their ambitions faster. With offices around the world, Adyen works with the likes of Facebook, Uber, H&M, eBay, and Microsoft. The cooperation with Fast Retailing as described in this merchant update underlines Adyen's continuous growth with current and new merchants over the years.
-
The Highly Anticipated Hong Kong Palace Museum Officially Opened its Doors
Hong Kong’s Victoria Harbour shines bright with a special edition of “A Symphony of Lights” this July alongside the new museum HONG KONG & LOS ANGELES--(BUSINESS WIRE)--After five years in the making, the prestigious Hong Kong Palace Museum (HKPM) opened on July 3, 2022 as the latest addition to Hong Kong’s arts and cultural offerings and the West Kowloon Cultural District. Joining a host of other landmark attractions on the storied Victoria Harbour waterfront, such as the newly opened M+ Museum and recently renovated Hong Kong Museum of Art, the HKPM elevates the city’s lineup of renowned museums and enriches its diversity of the arts and culture scene. What’s more, the much-loved “A Symphony of Lights” will bathe Victoria Harbour alongside the HKPM in lights, music and colors with an enchanting special edition program every night in July. Beginning at 8pm every night, the captivating spectacle will feature new elements including a fleet of six Star Ferries adorned with glittering light installations, and expand to include new landmarks, such as the HKPM and M+. Dane Cheng, Executive Director of the Hong Kong Tourism Board, said, “We are delighted to welcome the Hong Kong Palace Museum to Hong Kong’s artistic and cultural landscape and the West Kowloon Cultural District. Exciting, dynamic and constantly evolving, the district is brimming with activities and discoveries that underscore Hong Kong’s reputation as a leading destination for arts and culture lovers. We believe this world-class museum will generate even more interest for Hong Kong as an arts and cultural destination and solidify the city’s position as a center for international cultural exchange.” The HKPM is a must-visit attraction for arts and culture lovers, and a treasure trove of rare artifacts. It houses one of the world’s most impressive collections of Chinese ceramics and more than 900 works of art on loan from the esteemed Palace Museum in Beijing – among the largest and finest lend the Palace Museum has ever made to another cultural institution outside the Mainland since its establishment. The HKPM also displays 13 precious pieces borrowed from the Louvre as a testament to the museum’s role as an East-meets-West Centre for International Cultural Exchange. Contacts Media Contact: Anne Gomm Senior Manager, PR & Marketing Hong Kong Tourism Board USA 310-308-9805 (before 9 am) 323-938-7271 (office)
-
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Missfresh Limited (MF) on Behalf of Investors
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Missfresh Limited (“Missfresh” or the “Company”) (NASDAQ: MF) investors concerning the Company’s possible violations of the federal securities laws. If you suffered a loss on your Missfresh investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/missfresh-limited/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. On April 29, 2022, Missfresh disclosed that it could not timely file its fiscal 2021 annual report because it was conducting “an internal review of certain matters, including those relating to transactions between the Company and certain third-party enterprises.” On this news, Missfresh’s stock fell $0.19, or 27.7%, to close at $0.52 or April 29, 2022, thereby injuring investors. Then, on July 1, 2022, after the market closed. Missfresh announced that, based on substantial completion of the internal review, certain revenue reported during fiscal 2021 “may have been inaccurately recorded.” Specifically, the review identified “questionable transactions” carried out by the Next-Day Delivery Business Unit in 2021, including “undisclosed relationships between suppliers and customers, different customers or suppliers sharing the same contact information, and/or lack of supporting logistics information.” Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice: Persons with non-public information regarding Missfresh should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com. About GPM Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts Glancy Prongay & Murray LLP, Los Angeles Charles H. Linehan, 310-201-9150 or 888-773-9224 1925 Century Park East, Suite 2100 Los Angeles, CA 90067 www.glancylaw.comshareholders@glancylaw.com
-
InfiniBand Continues Leadership on TOP500 with 17 Percent Growth; 39th InfiniBand and RoCE Plugfest Bring Record Turnout
BEAVERTON, Ore.--(BUSINESS WIRE)--The InfiniBand® Trade Association (IBTA), a global organization dedicated to developing and furthering the adoption of RDMA technologies, today announced that InfiniBand grew 17 percent year-over-year, connecting 197 systems on the June 2022 TOP500 supercomputing list. InfiniBand also connects 62 of the Top100, making it the most used high-speed interconnect of the world’s top supercomputers. InfiniBand’s prominent presence on the TOP500 is indicative of its ability to provide the speed, low latency and scalability that the world’s top systems require. Leveraging Remote Direct Memory Access (RDMA) fabrics such as InfiniBand and RDMA over Converged Ethernet (RoCE) also offers data centers reliability, efficiency, and a highly interoperable environment for these systems to expand. “InfiniBand’s increased growth on the TOP500 and leadership on the Top100 is due to InfiniBand’s efficiency, scalability and fastest networking speeds that meet the industry’s demand for enhanced system and application performance,” said Brian Sparks, marketing working group chair for the IBTA. “Products are now becoming available which follow the IBTA’s NDR 400Gb/s InfiniBand specification, and we look forward to seeing them represented in future TOP500 lists.” Published twice a year and publicly available at www.top500.org, the TOP500 list ranks the world's most powerful computer systems according to the Linpack benchmark rating system. Record Turnout for 39th InfiniBand and RoCE Plugfest, Featuring NDR 400Gb/s InfiniBand and 400GbE This year’s IBTA Plugfest was the first testing instance of NDR 400Gb/s InfiniBand and 400GbE products, paving the way for the roll-out of the fastest interconnected systems in 2022. The event, hosted by University of New Hampshire InterOperability Lab (UNH-IOL) and in partnership with the Ethernet Alliance, provided the opportunity to perform interoperability testing of selected RDMA/RoCE-based Ethernet switch systems, adapter, NICS, and cables among a range of vendors. Key highlights from the InfiniBand and RoCE Plugfest: RDMA Cable Vendors: Amphenol, CONNPRO, NVIDIA, Panduit, The Siemon Company, TE Connectivity RDMA Device Vendors: Arista, Broadcom, NVIDIA and SANBlaze Test Equipment Vendors: Anritsu, Keysight, Rohde & Schwarz and Wilder Technologies 15 RDMA devices were tested for compliance and interoperability 141 RDMA cables were tested for compliance and interoperability. Copper and optical cable types included SFP, QSFP, QSFP-DD, OSFP and hybrids Keysight deployed a new NDR InfiniBand solution for testing 400Gb/s Active Optical Cables “The IBTA’s rigorous, independent third-party compliance and interoperability program ensures that each cable and device tested successfully meets end user needs and expectations of InfiniBand and RoCE ecosystems,” said Rupert Dance, chair of the IBTA compliance and interoperability working group. “The ability of IBTA Plugfest participants to interact with engineers from many device and cable vendors and test equipment providers while resolving problems in real time is essential to the success, compliance and interoperability of all InfiniBand and RoCE solutions.” The IBTA Plugfest is an invaluable benefit to members and creates a clear path to deliver to their customers products that are compliant to the InfiniBand and RoCE specifications and interoperable within the larger ecosystem. Each product that completes compliance and interoperability testing is compiled into the resulting InfiniBand Integrators’ List and RoCE Integrators’ List. The lists are technical resources that provide immense benefits to all end users deploying RDMA-based fabrics. A wide range of customers leverage these results when determining which products to use when designing or upgrading their systems. About the InfiniBand® Trade Association The InfiniBand® Trade Association was founded in 1999 and is chartered with maintaining and furthering the InfiniBand and the RoCE specifications. The IBTA is led by a distinguished steering committee that includes HPE, IBM, Intel Corporation and NVIDIA. Other members of the IBTA represent leading enterprise IT vendors who are actively contributing to the advancement of the InfiniBand and RoCE specifications. The IBTA markets and promotes InfiniBand and RoCE from an industry perspective through online, marketing and public relations engagements, and unites the industry through IBTA-sponsored technical events and resources. For more information on the IBTA, visit www.infinibandta.org. InfiniBand (TM/SM) and RoCE are trademark and service marks of the IBTA. Other names and brands are the property of their respective owners. Contacts Denise Jarrett-Weeks IBTA Administrator InfiniBand Trade Association Phone: 503.619.0565 administration@infinibandta.org
-
Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19
-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and Ascletis retains full global rights for its development and commercialization --This IND filing of ASC10 in the U.S. will accelerate Ascletis' global multi-center clinical studies on ASC10 and better position its oral drug pipeline of COVID-19 HANGZHOU, China and SHAOXING, China, July 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces that the Investigational New Drug (IND) application of ASC10, an oral inhibitor drug candidate targeting RNA-dependent RNA polymerase (RdRp) for Coronavirus Disease 2019 (COVID-19), has been filed to the U.S. Food and Drug Administration (FDA) after the Pre-IND consultation. Targeting RdRp of SARS-CoV-2 virus, ASC10 is an oral small molecule drug candidate for patients with COVID-19. ASC10 is an orally bioavailable, double prodrug of the antiviral nucleoside analog ASC10-A, which demonstrates potent inhibitory effect of RdRp of SARS-CoV-2 virus. ASC10-A demonstrated an excellent in vitro antiviral activity against multiple SARS-CoV-2 virus variants including Omicron in preclinical studies. Ascletis is committed to developing and manufacturing safe, effective, affordable oral drugs for COVID-19 globally. As a leading biotech company in China, Ascletis has completed IND filing of ASC10, an oral RdRp inhibitor drug candidate for COVID-19 with the U.S. FDA. At the same time, the IND filing of ASC10 in China is proceeding on track. About Ascletis Ascletis is an innovative R&D driven biotech listed on the Hong Kong Stock Exchange (1672.HK), covering the entire value chain from discovery and development to manufacturing and commercialization. Led by a management team with deep expertise and a proven track record, Ascletis focuses on three therapeutic areas with unmet medical needs from a global perspective: viral diseases, non-alcoholic steatohepatitis (NASH) and oncology. Through excellent execution, Ascletis rapidly advances its drug pipeline with an aim of leading in global competition. To date, Ascletis has three marketed products, i.e. ritonavir tablets, GANOVO® and ASCLEVIR®, and 20 drug candidates in its R&D pipeline. The most advanced drug candidates include ASC22 (CHB functional cure), ASC10 and ASC11 (oral small molecules for COVID-19 treatment), ASC40 (recurrent glioblastoma), ASC42 (PBC, primary biliary cholangitis), and ASC40 (acne). For more information, please visit www.ascletis.com.
